Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Files NDA For Oncology Anti-Nausea Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

Casopitant, follow-on to Zofran, is part of GSK’s larger plan to grow its oncology portfolio in supportive care.

You may also be interested in...



GSK’s Rezonic and Debiovision’s Sanvar To Get Advisory Committee Reviews In May

FDA has been digesting both applications for a considerable amount of time.

GSK’s Rezonic and Debiovision’s Sanvar To Get Advisory Committee Reviews In May

FDA has been digesting both applications for a considerable amount of time.

FDA “Approvable” Letter Requests Validation, Stability Data For Merck’s Emend IV

Firm will respond “within the next few months” to May 3 letter, Merck tells “The Pink Sheet” DAILY.

Topics

UsernamePublicRestriction

Register

PS067841

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel